Ben Sasse highlights a possible breakthrough for pancreatic cancer

Ben Sasse said his tumors have shrunk about 76% after taking RevMed’s experimental pill, which targets RAS mutations common in pancreatic cancer. RevMed expects Phase 3 results this quarter and says regulators want evidence the drug improves overall survival.

Former Senator Ben Sasse has drawn attention to an experimental pill being developed for pancreatic cancer after reporting a large reduction in his tumors while on the treatment. The drug, daraxonrasib from RevMed, is designed to target RAS mutations that drive many pancreatic cancers. The company and others have reported notable skin-related side effects in some patients, and RevMed says most rash cases have been low grade. RevMed expects to share Phase 3 trial data this quarter, and regulators have said they will need evidence the treatment improves overall survival. Key details: - Ben Sasse reported a roughly 76% reduction in tumor size after starting the treatment. - Daraxonrasib is described as broadly targeting RAS mutations, which are involved in about 90% of pancreatic cancer cases. - RevMed has said most skin reactions have been low grade and that reports of bleeding rashes are considered uncommon and anecdotal. - The company expects Phase 3 results this quarter, and the U.S. Food and Drug Administration has indicated it needs an overall survival benefit to support approval. - The article also notes market interest and speculation about acquisition interest from larger pharmaceutical companies. Summary: Reports of tumor shrinkage in an individual patient have increased attention on RevMed’s RAS-targeting approach. The upcoming Phase 3 readout, expected this quarter, will be central to whether the drug can show a survival benefit. Regulatory outcome and broader implications remain undetermined at this time.